Edition:
United States

Fennec Pharmaceuticals Inc (FENC.OQ)

FENC.OQ on NASDAQ Stock Exchange Capital Market

8.14USD
21 Sep 2018
Change (% chg)

$-0.03 (-0.37%)
Prev Close
$8.17
Open
$8.16
Day's High
$8.31
Day's Low
$8.08
Volume
34,139
Avg. Vol
30,175
52-wk High
$14.85
52-wk Low
$7.70

Chart for

About

Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the... (more)
No analyst recommendations are available for .

Overall

Beta: -0.76
Market Cap(Mil.): $197.55
Shares Outstanding(Mil.): 18.79
Dividend: --
Yield (%): --

Financials

  FENC.OQ Industry Sector
P/E (TTM): -- 108.33 32.69
EPS (TTM): -0.66 -- --
ROI: -50.94 1.50 12.72
ROE: -50.94 0.19 14.85

BRIEF-Fennec Pharmaceuticals Reports Q1 Loss Per Share Of $0.09

* FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

May 14 2018

BRIEF-Fennec Pharmaceuticals Receives Breakthrough Therapy Designation By FDA For Pedmark™

* FENNEC PHARMACEUTICALS RECEIVES BREAKTHROUGH THERAPY DESIGNATION BY FDA FOR PEDMARK™

Mar 27 2018

BRIEF-Fennec Says Phase 3 SIOPEL 6 Study Met Primary Endpoint

* FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES FISCAL YEAR ENDED DECEMBER 31, 2017 FINANCIAL RESULTS

Mar 26 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $142.88 +0.90
Roche Holding Ltd. (ROG.S) CHF235.15 +0.10
Roche Holding Ltd. (RO.S) CHF235.40 -1.20
Pfizer Inc. (PFE.N) $44.06 +0.31
Novartis AG (NOVN.S) CHF81.88 -0.06
Sanofi SA (SASY.PA) €74.50 -0.17
Abbott Laboratories (ABT.N) $69.05 +0.26
Merck & Co., Inc. (MRK.N) $71.10 +0.32
AstraZeneca plc (AZN.L) 5,670.00 +98.00
Amgen, Inc. (AMGN.OQ) $205.10 0.00

Earnings vs. Estimates

No consensus analysis data available.